Der Browser den Sie verwenden ist sehr alt.

Wir können daher nicht sicherstellen, dass jede Funktion (Gestaltung, Bilder und zusätzliche Funktionen) dieser Internetseite im vollen Umfang zur Verfügung steht. Bitte nutzen Sie eine aktuellere Browserversion.
Wir bitten um Ihr Verständnis.
Startseite > Forschung > Max-Eder-Nachwuchsgruppe > Publikationen/publications

Publications

by group members

Schewe D, Leupold JH, Boyd DD, Lengyel ER, Wang H, Grützner KU, Schildberg FW, Jauch KW, Allgayer H: Tumor-specific transcription factor binding to an AP-2/Sp1 element of the urokinase-receptor (u-PAR) promoter in a first large series of resected gastrointestinal cancers. Clin Cancer Res 9: 2267-2276, 2003.

Schewe D, Kappler M, Griese M: Instructions for infection control in outpatient care of patients with cystic fibrosis. Eur J Med Res 10(8): 345-351, 2005.

Schewe D, Biller T, Maurer G, Asangani IA, Leupold JH, Lengyel ER, Post S, Allgayer H: Combination analysis of activator protein-1 family members, Sp1 and an activator protein-2alpha-related factor binding to different regions of the urokinase receptor gene in resected colorectal cancers. Clin Cancer Res 11(24 Pt1): 8538-8548, 2006.

Maurer GD, Leupold JH, Schewe D, Biller T, Kates RE, Hornung HM, Lau-Werner U, Post S, Allgayer H. Analysis of specific transcriptional regulators as early predictors of independent prognostic relevance in resected colorectal cancer. Clin Cancer Res 13(4): 1123-1132, 2007.

Schewe D, Aguirre-Ghiso JA. ATF6α-Rheb-mTOR signaling promotes survival of dormant tumor cells in vivo. Proc Natl Acad Sci U S A 105(30): 10519-10524, 2008.

Schewe D, Aguirre-Ghiso JA. Inhibition of eIF2α dephosphorylation maximizes Bortezomib efficiency and eliminates quiescent multiple myeloma cells surviving proteasome inhibitor therapy. Cancer Research 69(4): 1545-1552, 2009.

Adam AP, George A, Iglesias BV, Schewe D, Ranganathan A, Kourtidis A, Conklin DS, Aguirre-Ghiso JA. Computational identification of a p38 SAPK regulated transcription factor network required for tumor cell quiescence. Cancer Research 69(14): 5664-5672, 2009.

Dörge P, Meissner B, Zimmermann M, Möricke A, Schrauder A, Bouquin JP, Schewe D, Harbott J, Teigler-Schlegel A, Ratei R, Ludwig WD, Koehler R, Bartram CR, Schrappe M, Stanulla M, Cario G. IKZF1 deletion is an independent predictor of outcome in pediatric acute lymphoblastic leukemia treated according to the ALL-BFM 2000 protocol. Haematologica 98(3): 428-432, 2013.

Ben-Batalla I, Schultze A, Wroblewski M, Erdmann R, Heuser M, Waizenegger JS, Riecken K, Binder M, Schewe D, Sawall S, Witzke V, Cubas-Cordova M, Janning M, Wellbrock J, Fehse B, Hagel C, Krauter J, Ganser A, Lorens JB, Fiedler W, Carmeliet P, Pantel K, Bokemeyer C, Loges S. Axl, a prognostic and therapeutic target in acute myeloid leukemia mediates paracrine crosstalk of leukemia cells with bone marrow stroma. Blood 122(14): 2443-2452, 2013.

Bragado PE, Estrada Y, Parikh F, Krause S, Capobianco C, Farina HG, Schewe DM, Aguirre-Ghiso JA: TGF-β2 dictates disseminated tumour cell fate in target organs through TGF-β-RIII and p38α/β signalling. Nat Cell Biol 15(11): 1351-1361, 2013.

Krause S, Pfeiffer C, Strube S, Alsadeq A, Fedders H, Vokuhl C, Loges S, Waizenegger J, Ben-Batalla I, Cario G, Möricke A, Stanulla M, Schrappe M, Schewe D. Mer tyrosine kinase promotes the survival of t(1;19) positive acute lymphoblastic leukemia (ALL) in the central nervous system (CNS). Blood 125:820-830, 2015.
Frishman-Levy L, Shemesh A, Bar-Sinai A, Ma C, Ni Z, Frenkel S, Muench V, Bruckmueller H, Vokuhl C, Debatin K-M, Eckert C, Stanulla M, Schrappe M, Campbell KS, Loewenthal R, Schewe D, Hochman J, Meyer LH, Kaufman D, Cario G, Porgador A, Izraeli S. Central Nervous System Acute Lymphoblastic Leukemia: role of Natural Killer Cells. Blood 125(22):3420-31, 2015.
 
Fritsche H, Heilmann T, Tower RJ, Hauser C, Campbell GM, von Au A, Schewe D, Hübner S, Zöller M, Becker T, Glüer CC, Kalthoff H, Schem C, Trauzold A. TRAIL-R2 promotes skeletal metastasis in breast cancer. Oncotarget 6(11):9502-16, 2015.
 
Adomako A, Calvo V, Biran N, Osman K, Chari A, Paton JC, Paton AW, Moore K, Schewe D, Aguirre-Ghiso JA. Identification of markers that functionally define a quiescent multiple myeloma cell sub-population surviving bortezomib treatment.BMC Cancer 15(1):444, 2015.
 
Alsadeq A, Strube S, Krause S, Carlet M, Jeremias I, Vokuhl C, Loges S, Aguirre-Ghiso JA, Trauzold A, Cario G, Stanulla M, Schrappe M, Schewe D. Effects of p38α/β inhibition on acute lymphoblastic leukemia (ALL) proliferation and survival in vivo. Leukemia, 2015 in press.